Steven Schain of Smart-Counsel LLC. FDA's Psychedelic Drug Clinical Trial Guidance Aims to Stimulate Funding, Acceptance
Forming the federal government's first directive on how to research psychedelics' medical application, the guidance removes this multibillion dollar industry's two major stumbling blocks: public acceptance and funding.
August 25, 2023 at 11:33 AM
7 minute read
Marijuana
Providing critical tools for investigating psychedelics use in treating medical conditions, the U.S. Food and Drug Administration (FDA) issued "Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry" (guidance) in June 2023.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View All
Why Cannabis Testing and Labeling Standardization Is Long Overdue
DEA Rescheduling, Pa. Legalization Efforts May Breathe New Life Into Cannabis Practices
4 minute read
Trending Stories
- 1The Law Firm Disrupted: Playing the Talent Game to Win
- 2A&O Shearman Adopts 3-Level Lockstep Pay Model Amid Shift to All-Equity Partnership
- 3Preparing Your Law Firm for 2025: Smart Ways to Embrace AI & Other Technologies
- 4BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 5A RICO Surge Is Underway: Here's How the Allstate Push Might Play Out
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
